Discover 86 paid clinical trials in Anchorage, Alaska. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 86
Active & Responsive
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
for
Lymphoma, Follicular
Location: Anchorage AK, Seattle WA, San Francisco CA,
Sponsor: Celgene
Sex: All
Age: 18+
Code: NCT06425302
Phase2, Recruiting
Active & Responsive
Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
for
Non-small Cell Lung Cancer
Location: Anchorage AK, Hastings NE, Cedar Rapids IA,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06712316
Phase2, Phase3, Recruiting
Active & Responsive
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
for
Obstructive Hypertrophic Cardiomyopathy
Location: Anchorage AK, Seattle WA, San Francisco CA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT05489705
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
for
Breast Cancer
Location: Anchorage AK, Mount Vernon WA, Seattle WA, Portland OR,
Sponsor: Agendia
Sex: All
Age: 18+
Code: NCT03053193
Recruiting
Active & Responsive
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma